Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mitsuyuki, Shimada"'
Autor:
Taisuke, Tawaraishi, Atsuko, Ochida, Yuichiro, Akao, Sachiko, Itono, Masahiro, Kamaura, Thamina, Akther, Mitsuyuki, Shimada, Stacie, Canan, Sanjoy, Chowdhury, Yafeng, Cao, Kevin, Condroski, Ola, Engkvist, Amanda, Francisco, Sunil, Ghosh, Rina, Kaki, John M, Kelly, Chiaki, Kimura, Thierry, Kogej, Kazuya, Nagaoka, Akira, Naito, Garry, Pairaudeau, Constantin, Radu, Ieuan, Roberts, David, Shum, Nao-Aki, Watanabe, Huanxu, Xie, Shuji, Yonezawa, Osamu, Yoshida, Ryu, Yoshida, Charles, Mowbray, Benjamin, Perry
Publikováno v:
Journal of medicinal chemistry.
Probing multiple proprietary pharmaceutical libraries in parallel via virtual screening allowed rapid expansion of the structure-activity relationship (SAR) around hit compounds with moderate efficacy against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::098120064a818c49ef6eba16a4ffb203
https://pubmed.ncbi.nlm.nih.gov/36607408
https://pubmed.ncbi.nlm.nih.gov/36607408
Publikováno v:
Pharmacological Reports. 70:172-177
The effects of farnesoid X receptor (FXR) antagonists on plasma lipid profile in mice have not been investigated thus far. The aim of this study was to investigate the antidyslipidemic effects of an FXR antagonist in dyslipidemic mice, and to clarify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f913c05f36fccdc4e7870e0d066ea3d1
https://doi.org/10.1016/j.pharep.2017.07.010
https://doi.org/10.1016/j.pharep.2017.07.010
Publikováno v:
European Journal of Pharmacology. 723:108-115
We aimed to elucidate the mechanism underlying the anti-dyslipidemic effect of compound-T3, a farnesoid X receptor antagonist, by investigating its effects on hepatic lipid metabolism in non-human primates. We administered lipid-lowering drugs for 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c928445b9bebb28b8c57c7b4e57dd056
https://doi.org/10.1016/j.ejphar.2013.10.048
https://doi.org/10.1016/j.ejphar.2013.10.048
Autor:
Mitsuyuki Shimada, Hiroshi Miki, Kouhei Asano, Masaki Ogino, Yoshihisa Nakada, Toshihiro Yamamoto, Hiroshi Yamaguchi, Minori Masago, Norikazu Tamura, Kazuko Aoki, Koki Kato
Publikováno v:
European Journal of Pharmacology. 640:243-249
Coenzyme A (CoA):diacylglycerol acyltransferase 1 (DGAT1) is 1 of the 2 known DGAT enzymes that catalyze the final and only committed step in triacylglycerol synthesis; this enzyme is considered to be a potential therapeutic target in metabolic disor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c47d4c79196895bf4987370a7fa79251
https://doi.org/10.1016/j.ejphar.2010.04.050
https://doi.org/10.1016/j.ejphar.2010.04.050
Autor:
Emiko Shinozawa, Hiroko Yamakawa, Ryuichi Tozawa, Yuichiro Amano, Megumi Haba, Mitsuyuki Shimada
Publikováno v:
Pharmacology Research & Perspectives
We attempted to clarify the therapeutic capability of antagonists of the farnesoid X receptor (FXR), a nuclear receptor that regulates lipid and bile acid metabolism. Herein, we report the antidyslipidemic effects of a novel synthesized FXR antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7c5c47611bccef64dae1212d9819152
https://doi.org/10.1002/prp2.390
https://doi.org/10.1002/prp2.390
Autor:
Yoshihisa Nakada, Minori Masago, Mitsuyuki Shimada, Toshihiro Yamamoto, Kouhei Asano, Kazuko Aoki, Hiroshi Miki, Norikazu Tamura, Koki Kato, Masaki Ogino
Publikováno v:
Chemical and Pharmaceutical Bulletin. 58:673-679
In a program to discover new small molecule diacylglycerol acyltransferase (DGAT)-1 inhibitors, screening of our in-house chemical library was carried out using recombinant human DGAT-1 enzyme. From this library, the lead compound 1a was identified a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::290ff49f8f9e87b4a037af867ededf87
https://doi.org/10.1248/cpb.58.673
https://doi.org/10.1248/cpb.58.673
Autor:
Kevin Bacon, Keiko Fukushima, Koriyama Yuji, Yamauchi Megumi, Nunami Noriko, Mitsuyuki Shimada, Yoshino Takashi, Karl Ziegelbauer, Akihiko Watanabe, Tsutomu Masuda, Hiroki Sato, Toshiki Murata, Timothy B. Lowinger, Kinji Fuchikami, Sachiko Sakakibara, Hiroshi Komura, Takuya Shintani
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 14:4019-4022
A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as I kappaB kinase beta (IKK-beta) inhibitors. Modification of a novel IKK-beta inhibitor 1 (IKK-beta IC(50)=1500 nM, Cell IC(50)=8000 nM) at th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77aace4de90cf1e1cb250eddf70fa353
https://doi.org/10.1016/j.bmcl.2004.05.041
https://doi.org/10.1016/j.bmcl.2004.05.041
Autor:
Yoshino Takashi, Keisuke Takeshita, Hiroshi Kadono, Sachiko Sakakibara, Kevin Bacon, Makoto Shimazaki, Mitsuyuki Shimada, Takuya Shintani, Katsuya Sakai, Toshiro Niki, Toshiki Murata, Tsutomu Masuda, Masaomi Umeda, Timothy B. Lowinger, Hisayo Inbe, Karl Ziegelbauer, Kinji Fuchikami
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 13:913-918
IkappaB kinase beta (IKK-beta) is a serine-threonine protein kinase critically involved in the activation of the transcription factor Nuclear Factor kappa B (NF-kappaB) in response to various inflammatory stimuli. We have identified a small molecule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90956578ea913259b1e747c2766153e6
https://doi.org/10.1016/s0960-894x(02)01046-6
https://doi.org/10.1016/s0960-894x(02)01046-6
Autor:
Mitsuyuki Shimada, Shotaro Miura, Eiichiro Ishikawa, Emiko Shinozawa, Ryuichi Tozawa, Ryutaro Adachi, Yuichiro Amano
Publikováno v:
Life sciences. 108(1)
Aims We previously reported anti-dyslipidemic effects of a farnesoid X receptor antagonist in monkeys. In this study, we compared the cholesterol-lowering effects of single and combined administration of a farnesoid X receptor antagonist, compound-T8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c30f7dce77ebffc53670be9d44967d4
https://pubmed.ncbi.nlm.nih.gov/24805868
https://pubmed.ncbi.nlm.nih.gov/24805868
Publikováno v:
Life sciences. 106(1-2)
Aims We investigated antidyslipidemic effects of a farnesoid X receptor antagonist compound-T3 in non-human primates as a novel treatment approach for dyslipidemia. Main methods Cynomolgus monkeys were fed a high-fat diet over 3 weeks. Drugs were adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0a742fd527dff680798a35511995146
https://pubmed.ncbi.nlm.nih.gov/24787893
https://pubmed.ncbi.nlm.nih.gov/24787893